Myeloproliferative neoplasms, version 2.2017: Clinical Practice Guidelines in oncology

Ruben Mesa; Catriona Jamieson; Ravi Bhatia; Michael W. Deininger; Aaron T. Gerds; Ivana Gojo; Jason Gotlib; Krishna Gundabolu; Gabriela Hobbs; Rebecca B. Klisovic; Patricia Kropf; Sanjay R. Mohan; Stephen Oh; Eric Padron; Nikolai Podoltsev; Daniel A. Pollyea; Raajit Rampal; Lindsay A.M. Rein; Bart Scott; David S. Snyder; Brady L. Stein; Srdan Verstovsek; Martha Wadleigh; Eunice S. Wang; Mary Anne Bergman; Kristina M. Gregory; Hema Sundar

doi:10.6004/jnccn.2016.0169

Myeloproliferative neoplasms, version 2.2017: Clinical Practice Guidelines in oncology

Ruben Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Rebecca B. Klisovic, Patricia Kropf, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolai Podoltsev, Daniel A. Pollyea, Raajit Rampal, Lindsay A.M. Rein, Bart Scott, David S. SnyderBrady L. Stein, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, Hema Sundar

Research output: Contribution to journal › Review article › peer-review

56 Scopus citations

Abstract

Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagnosis and the management of patients with MPNs have evolved since the identification of mutations that activate the JAK pathway (JAK2, CALR, and MPL mutations) and the development of targeted therapies has resulted in significant improvements in disease-related symptoms and quality of life. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnostic workup of MPN (MF, PV, and ET), risk stratification, treatment, and supportive care strategies for the management of MF.

Original language	English
Pages (from-to)	1572-1611
Number of pages	40
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	14
Issue number	12
DOIs	https://doi.org/10.6004/jnccn.2016.0169
State	Published - Dec 1 2016

Access to Document

10.6004/jnccn.2016.0169

Cite this

Mesa, R., Jamieson, C., Bhatia, R., Deininger, M. W., Gerds, A. T., Gojo, I., Gotlib, J., Gundabolu, K., Hobbs, G., Klisovic, R. B., Kropf, P., Mohan, S. R., Oh, S., Padron, E., Podoltsev, N., Pollyea, D. A., Rampal, R., Rein, L. A. M., Scott, B., ... Sundar, H. (2016). Myeloproliferative neoplasms, version 2.2017: Clinical Practice Guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 14(12), 1572-1611. https://doi.org/10.6004/jnccn.2016.0169

@article{cbc73b38e92542dcbb4924c13a487f73,

title = "Myeloproliferative neoplasms, version 2.2017: Clinical Practice Guidelines in oncology",

abstract = "Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagnosis and the management of patients with MPNs have evolved since the identification of mutations that activate the JAK pathway (JAK2, CALR, and MPL mutations) and the development of targeted therapies has resulted in significant improvements in disease-related symptoms and quality of life. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnostic workup of MPN (MF, PV, and ET), risk stratification, treatment, and supportive care strategies for the management of MF.",

author = "Ruben Mesa and Catriona Jamieson and Ravi Bhatia and Deininger, {Michael W.} and Gerds, {Aaron T.} and Ivana Gojo and Jason Gotlib and Krishna Gundabolu and Gabriela Hobbs and Klisovic, {Rebecca B.} and Patricia Kropf and Mohan, {Sanjay R.} and Stephen Oh and Eric Padron and Nikolai Podoltsev and Pollyea, {Daniel A.} and Raajit Rampal and Rein, {Lindsay A.M.} and Bart Scott and Snyder, {David S.} and Stein, {Brady L.} and Srdan Verstovsek and Martha Wadleigh and Wang, {Eunice S.} and Bergman, {Mary Anne} and Gregory, {Kristina M.} and Hema Sundar",

note = "Publisher Copyright: {\textcopyright} 2016 JNCCN-Journal of the National Comprehensive Cancer Network.",

year = "2016",

month = dec,

day = "1",

doi = "10.6004/jnccn.2016.0169",

language = "English",

volume = "14",

pages = "1572--1611",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "12",

}

Mesa, R, Jamieson, C, Bhatia, R, Deininger, MW, Gerds, AT, Gojo, I, Gotlib, J, Gundabolu, K, Hobbs, G, Klisovic, RB, Kropf, P, Mohan, SR, Oh, S, Padron, E, Podoltsev, N, Pollyea, DA, Rampal, R, Rein, LAM, Scott, B, Snyder, DS, Stein, BL, Verstovsek, S, Wadleigh, M, Wang, ES, Bergman, MA, Gregory, KM & Sundar, H 2016, 'Myeloproliferative neoplasms, version 2.2017: Clinical Practice Guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 14, no. 12, pp. 1572-1611. https://doi.org/10.6004/jnccn.2016.0169

TY - JOUR

T1 - Myeloproliferative neoplasms, version 2.2017

T2 - Clinical Practice Guidelines in oncology

AU - Mesa, Ruben

AU - Jamieson, Catriona

AU - Bhatia, Ravi

AU - Deininger, Michael W.

AU - Gerds, Aaron T.

AU - Gojo, Ivana

AU - Gotlib, Jason

AU - Gundabolu, Krishna

AU - Hobbs, Gabriela

AU - Klisovic, Rebecca B.

AU - Kropf, Patricia

AU - Mohan, Sanjay R.

AU - Oh, Stephen

AU - Padron, Eric

AU - Podoltsev, Nikolai

AU - Pollyea, Daniel A.

AU - Rampal, Raajit

AU - Rein, Lindsay A.M.

AU - Scott, Bart

AU - Snyder, David S.

AU - Stein, Brady L.

AU - Verstovsek, Srdan

AU - Wadleigh, Martha

AU - Wang, Eunice S.

AU - Bergman, Mary Anne

AU - Gregory, Kristina M.

AU - Sundar, Hema

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagnosis and the management of patients with MPNs have evolved since the identification of mutations that activate the JAK pathway (JAK2, CALR, and MPL mutations) and the development of targeted therapies has resulted in significant improvements in disease-related symptoms and quality of life. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnostic workup of MPN (MF, PV, and ET), risk stratification, treatment, and supportive care strategies for the management of MF.

AB - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagnosis and the management of patients with MPNs have evolved since the identification of mutations that activate the JAK pathway (JAK2, CALR, and MPL mutations) and the development of targeted therapies has resulted in significant improvements in disease-related symptoms and quality of life. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnostic workup of MPN (MF, PV, and ET), risk stratification, treatment, and supportive care strategies for the management of MF.

UR - http://www.scopus.com/inward/record.url?scp=85005992065&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2016.0169

DO - 10.6004/jnccn.2016.0169

M3 - Review article

C2 - 27956542

AN - SCOPUS:85005992065

SN - 1540-1405

VL - 14

SP - 1572

EP - 1611

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 12

ER -

Myeloproliferative neoplasms, version 2.2017: Clinical Practice Guidelines in oncology

Abstract

Access to Document

Other files and links

Fingerprint

Cite this